TPCN2 and neurodegenerative disease: There is clearly a need to decipher the effects of different modes of TPC2 activation in neurodegenerative disease models, preferably in human iPSC-derived neuronal models, i.e., the differences in NAADP versus PI(3,5)P2-mediated channel activation, the possibility of NAADP mediated TPC2 hyperactivity in certain neurodegenerative disease models as well as long-term versus short-term inhibition of TPC2 in different disease models and disease conditions.